4//SEC Filing
EndoChoice Holdings, Inc. 4
Accession 0001623919-16-000099
CIK 0001623919operating
Filed
Nov 22, 7:00 PM ET
Accepted
Nov 23, 10:22 AM ET
Size
18.4 KB
Accession
0001623919-16-000099
Insider Transaction Report
Form 4
Gilreath Mark
DirectorSee remarks.
Transactions
- Disposition to Issuer
Common stock, par value $0.001 per share
2016-11-22$8.00/sh−74,755$598,040→ 0 total(indirect: By Trust) - Disposition to Issuer
Common stock, par value $0.001 per share
2016-11-22$8.00/sh−1,818$14,544→ 0 total(indirect: By Daughter) - Disposition to Issuer
Employee Stock Option (right to buy)
2016-11-22−4,569→ 0 totalExercise: $2.83From: 2009-01-01Exp: 2019-01-01→ Common stock, par value $0.001 per share (4,569 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2016-11-22−140,739→ 0 totalExercise: $16.01Exp: 2025-08-14→ Common stock, par value $0.001 per share (140,739 underlying) - Disposition to Issuer
Common stock, par value $0.001 per share
2016-11-22$8.00/sh−12,243$97,944→ 0 total(indirect: By Trust) - Disposition to Issuer
Common stock, par value $0.001 per share
2016-11-22$8.00/sh−789,270$6,314,160→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2016-11-22−71,645→ 0 totalExercise: $5.31Exp: 2026-03-29→ Common stock, par value $0.001 per share (71,645 underlying) - Disposition to Issuer
Common stock, par value $0.001 per share
2016-11-22$8.00/sh−3,200$25,600→ 0 total(indirect: By Spouse)
Footnotes (5)
- [F1]Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.
- [F2]The total direct shares shown includes 3,063 shares purchased in the issuer's employee stock purchase plan on June 30, 2016.
- [F3]This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share.
- [F4]Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger.
- [F5]This option was cancelled pursuant to the Merger. Since the exercise price of this option exceeded the merger consideration of $8.00 per common shares, no cash payment was received by the reporting person.
Documents
Issuer
EndoChoice Holdings, Inc.
CIK 0001623919
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001623919
Filing Metadata
- Form type
- 4
- Filed
- Nov 22, 7:00 PM ET
- Accepted
- Nov 23, 10:22 AM ET
- Size
- 18.4 KB